Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bioventus Inc. - Class A Common Stock (NQ:BVS)

6.700 +0.050 (+0.75%)
Streaming Delayed Price Updated: 10:12 AM EDT, Oct 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bioventus Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports Second Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports First Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports Third Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports Second Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports First Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
From Bioventus, Inc.
Via GlobeNewswire
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
From Bioventus, Inc.
Via GlobeNewswire
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Bioventus Names Robert Claypoole as President and Chief Executive Officer
Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin Growth 
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
From Bioventus, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.